tbuckley/cabot-search huggingface dataset:
Improvement of existing risk classifications in primary gastrointestinal stromal tumors (GIST).
Authors: Piotr Rutkowski, Elzbieta Bylina, Daniel Rabczenko, Agnieszka Wozniak, Maria Debiec-Rychter, Janusz A. Siedlecki
Journal: Journal of Clinical Oncology (2014)

10517 Background: The reliable risk assessment of relapse and survival after initial resection are needed for a proper selection of GIST patients for adjuvant therapy. Methods: We analyzed group of registered prospectively 692 primary GISTs CD117(+) treated surgically with curative intention between 1999-2009, with no adjuvant imatinib. Median follow-up time was 34 months. We analyzed the factors influencing on 1-year and 5-year disease-free survival time (DFS; calculated from the date radical operation) and 5-year overall survival (OS). We also compared the reliability of existing risk classification (NIH, NCCN-AFIP according to Miettinen-Lasota, TNM-AJCC, revised NIH according to Joensuu, nomograms according to Gold et al and according to Rossi et al) using Receiver Operating Characteristic (ROC) curves tests. Results: With univariate analysis the following negative prognostic factors for DFS have been identified: male sex, mitotic index 5-10/50 and >10/50 HPF (p<0.001), primary tumor size 5-10 cm and >10 cm (p<0.001), non-gastric location (p<0.001), R1 surgery or tumor rupture (p<0.001), presence of exon 11 KIT 557_558 del or exon 9 KIT mutations (p=0.009). The negative prognostic factors for OS were: age <40 (p=0.045), mitotic index 5-10/50 and >10/50 HPF (p<0.001), primary tumor size 5-10 cm and >10 cm(p<0.001), R1 surgery or tumor rupture (p<0.001). These factors were found also statistically significant in multivariate analyses. All existing risk classification demonstrated prognostic value for assessment of differences in DFS and OS, and we have not found significant differences between them when compared with ROC tests. In addition, the reliability of all these classifications was improved when gender/age and mutational status were added. The additive value of mutational status for better risk assessment was the most significant when used in intermediate risk groups according to different classifications (p<0.01). Conclusions: The reliability of existing classifications for the risk assessment of disease recurrence and death after resection of primary GIST can be improved by adding mutational status, with the mostly significant refinement of better stratifications in intermediate risk groups.
Favorable Influence of Rituximab with High Dose Sequential Chemotherapy (R-HDS) Programs and Autologous Stem Cell Transplantation (ASCT) in Salvage Treatment for Patients with Refractory or Relapsed B-Cell Non-Hodgkin’s Lymphoma.
Authors: Milena Pintimalli, Michael Mian, Andrea Rossi, Marco Sorio, Fabio Benedetti, Giovanni Pizzolo, Atto Billio, Tiziano Barbui, Alessandro Rambaldi, Sergio Cortelazzo
Journal: Blood (2006)
Activity of Coagulation Factors IX and XIII and Fibrinogen are Increased in “Obese Non-Alcoholic Fatty Liver Disease” but not in “PNPLA3 Non-Alcoholic Fatty Liver Disease”
Authors: S. Lallukka, M. Orho-Melander, N. Lundbom, V.M. Olkkonen, H. Yki-Järvinen
Journal: Journal of Hepatology (2016)
Development of a new, sensitive assay for circulating tumor cell detection in prostate cancer.
Authors: V. O. Melnikova, D. W. Davis, D. Mittelman, Y. Zhang, G. S. Holz, G. K. Doshi, P. Cen, R. J. Amato
Journal: Journal of Clinical Oncology (2010)

e15015 Background: Circulating tumor cells (CTC) have emerged as a valuable cancer biomarker. When measured by the FDA-approved CellSearch CTC Kit from Veridex, the number of CTCs in the peripheral blood correlates with the overall and progression free survival in patients with metastatic prostate, breast, and colorectal cancers. Here, we further evaluated the association of CTCs with conventional biomarkers that measure disease burden in prostate cancer patients and developed methodology to increase the CTC yield for molecular profiling. Methods: We investigated CTCs obtained from 35 men with metastatic hormone refractory prostate cancer. CTCs were isolated from blood using the CellSearch CTC Kit, which immunomagnetically isolates EpCAM+ cells and enumerates CK+/DAPI+/CD45- cells. The association between CTC number and PSA, alkaline phosphatase or LDH were analyzed using Spearman correlation method. To increase the CTC recovery, we validated the CellSearch CTC Profile Kit, which allows to recover EpCAM+ cells and enumerate CTCs using Laser Scanning Cytometry (LSC) analysis. FISH for PTEN, TMPRSS-ERG and AR was performed on CTCs. Results: Fifteen patients (43%) had zero CTCs and 20 (57%) had one or more CTCs, as measured with CellSearch CTC Kit. CTCs correlated with conventional biomarkers such as mean PSA (p=0.038), mean alkaline phosphatase (p=0.035), and mean LDH (p<0.0001). The CTC Profile Kit allowed isolation of CTCs from the CTC-negative (as detected by standard kit) samples and yielded higher CTC counts (range 0 to 56 vs. 14 to 180). Increased recovery permitted the re-localization of CTCs to determine the status of PTEN, TMPRSS-ERG and AR deletion, fusion or amplification by FISH. Conclusions: Our results indicate that CTC counts correlate with standard markers of prostate cancer. Further, the CellSearch Profile Kit permits higher yield of CTC isolation thus enabling molecular characterization of CTCs. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration ApoCell, Inc.
Evaluation of Efficacy and Safety of Percutaneous Aspiration Sclerotherapy of Simple Hepatic Cysts, a Systematic Review
Authors: T.F. Wijnands, A.P. Gortjes, T.J. Gevers, S. Jenniskens, L.J. Schultze Kool, A. Potthoff, M. Ronot, J.P. Drenth
Journal: Journal of Hepatology (2016)
Changes of the Gut Microbiota in Patients with Obesity, Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease versus Healthy Controls
Authors: E. Nistal, M.B. Pomar, M.T.A. Loste, C. Alonso, M.A. Cabezudo, M. Jimenez, P. Iruzubieta, M. Molina-Edesa, E. Fábrega, J.M. García-Lobo, J.L. Olcoz, J. Crespo
Journal: Journal of Hepatology (2016)
IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma
Authors: Song Gao, Yan Sun, Xuebin Zhang, Limei Hu, Yuexin Liu, Corrine Yingxuan Chua, Lynette M. Phillips, He Ren, Jason B. Fleming, Huamin Wang, Paul J. Chiao, Jihui Hao, Wei Zhang
Journal: Cancer Research (2016)

Abstract The molecular basis underlying the particularly aggressive nature of pancreatic ductal adenocarcinoma (PDAC) still remains unclear. Here we report evidence that the insulin-like growth factor–binding protein IGFBP2 acts as a potent oncogene to drive its extremely malignant character. We found that elevated IGFBP2 expression in primary tumors was associated with lymph node metastasis and shorter survival in patients with PDAC. Enforced expression of IGFBP2 promoted invasion and metastasis of PDAC cells in vitro and in vivo by inducing NF-κB–dependent epithelial–mesenchymal transition (EMT). Mechanistic investigations revealed that IGFBP2 induced the nuclear translocation and phosphorylation of the p65 NF-κB subunit through the PI3K/Akt/IKKβ pathway. Conversely, enforced expression of PTEN blunted this signaling pathway and restored an epithelial phenotype to PDAC cells in the presence of overexpressed IGFBP2. Overall, our results identify IGFBP2 as a pivotal regulator of an EMT axis in PDAC, the activation of which is sufficient to confer the characteristically aggressive clinical features of this disease. Cancer Res; 76(22); 6543–54. ©2016 AACR.
Pattern of failure after hepatic arterial concurrent chemoradiotherapy for locally advanced hepatocellular carcinoma.
Authors: Jinsil Seong, Haejung Cha, Woongsub Keum, Hongin Yoon, Kwanghyub Han
Journal: Journal of Clinical Oncology (2012)

299 Background: We have previously reported outcome of concurrent chemoradiotherapy (CCRT) in advanced hepatocellular carcinoma (HCC) with median survival 13.1 months. We further analyzed patterns of failure as well as related clinical factors. Methods: Retrospective cohort analysis was done for 161 HCC patients given CCRT between May 2000 and August 2009. CCRT involved median radiation dose 45 Gy/25 fractions and intraarterial 5-Fu 500 mg thru chemoport. Patterns of failure were categorized; 1) infield, 2) intrahepatic-outfield, and 3) extrahepatic failure. Clinical factors were analyzed using Kaplan-Meyer method and multivariate analysis using Cox-proportional hazard model. Results: The median age was 55 years and most patients had Child-Pugh A (92%). Infield, intrahepatic-outfield, and extrahepatic failure were observed in 47 (30%), 67 (42%), and 66 patients (42%), respectively. For infield failure, median progression free survival (PFS) of patients treated with CCRT as initial treatment has not yet been reached compared with that in patients with treatment history before CCRT. (Median PFS NR vs. 17 months, p=0.001) For intrahepatic-outfield failure, pretreatment AFP &gt; 500 ng/mL was associated with high incidence of this failure (Median PFS 22 months vs. 10 months, p=0.006). For extrahepatic failure, Age &lt; 55 years and pretreatment AFP &gt; 500 were significant factors for failure, which were also significant in multivariate analysis. Median PFS has not been reached in age &lt;55 years and pretreatment AFP ≤ 500 ng/mL, compared with 10 months in age &gt;55 years (p=0.011) and 14 months in pretreatment AFP &gt; 500 ng/mL. (p=0.042). Conclusions: Infield, intrahepatic-outfield, and extrahepatic failure were observed in similar proportion. Pretreatment AFP ≥ 500 ng/mL was significant factor for intrahepatic-outfield and extrahepatic failure. Ages &lt;55 years increased incidence of extrahepatic failure. Treatment history before CCRT was associated with infield failure.
Use of the G-CSF Biosimilar Ratiograstim® to Mobilize Peripheral Stem Cells in Healthy Donors for Allogeneic Stem Cell Transplantation
Authors: Michael Schmitt, Diestel Lena, Catarina Schneider, Xun Xu, Kersten Borchert, Dietrich Gläser, Inken Hilgendorf, Robert Scheuerlein, Mathias Freund, Anita Schmitt
Journal: Blood (2011)
Efficacy and Safety of Simeprevir plus Sofosbuvir plus Ribavirin Flat Dose in a Population of Naive and Experienced HCV Genotype 1 Cirrhotic Elderly Patients: A Real World Experience from CLEO Group
Authors: A.M. Pellicelli, V.P. Palitti, P. Vignally, A. Moretti, P. Tarquini, G. Scifo, V. Messina, A. Ascione, A. Izzi, C. D’Ambrosio, R. Villani, L. Fondacaro, L. Fontanella, P. Guarascio, L. Alessio, E.D amico, G.M. Ettorre, M. Marignani, P. Begini, G. Cerasari, A. Barlattani, O. Armignacco, G. Barbarini
Journal: Journal of Hepatology (2016)
Transforming a unit’s culture to improve clinical outcomes.
Authors: Heidi Tonne, Theresa Woodrum, Michael Romano
Journal: Journal of Clinical Oncology (2016)

243 Background: Leadership identified an unhealthy work environment existed in our Oncology Hematology Special Care Unit (OHSCU). This was evidenced by increased turnover, low National Database of Nursing Quality Indicators (NDNQI), and nurse sensitive quality indicator scores. In the fall of 2014 changes were made to the unit with a goal of creating within the unit a culture of clinical excellence, engagement, professionalism, accountability, and improve staff satisfaction. Methods: Leadership met to define the future state of the unit and develop a vision statement. The Quality Manager met with our Unit based Council (UBC) to review data, discuss shared accountability between leadership, and staff and the impact each individual can have on culture and clinical outcomes. Organizational Development facilitated staff focus groups without unit leadership present. Questions asked included: What behaviors would you like to see more or less of? What is your role in supporting change? Focus group results were shared with staff, and guided the development of an OHSCU Guidelines for Professional Behavior. Leadership met with lead staff nurses to discuss their willingness to embrace cultural change and unit vision. Leads completed the Crucial Conversations Class to help them provide immediate, direct, and specific feedback to staff. Leadership met with each staff member to review the guidelines and discuss their commitment to support change. The unit vision was incorporated in all written and verbal communication with staff. Changes in leadership behaviors included increased leadership presence on nights and weekends, daily rounding with patients and staff, and increased amount of positive feedback. Results: Fall injury scores were decreased from 1.55 to 0.25 per 1,000 patient days, target of 0.72. OHSCU has had no catheter associated urinary tract infections (CAUTI) or pressure ulcers in the last 17 months. Patient satisfaction scores have consistently improved over the last nine months. Response of hospital staff scores have increased from 53.6 to 70.9 and currently 90% of patients rate the hospital as a 9 or 10. Conclusions: Through focused efforts and thoughtful actions, it is possible to change the culture of a unit and have a positive impact on quality metrics.
MiR 31 3p as a predictive biomarker of cetuximab efficacy effect in metastatic colorectal cancer (mCRC) patients enrolled in FIRE-3 study.
Authors: Pierre Laurent-Puig, Marie-Lise Grisoni, Volker Heinemann, Franck Bonnetain, Karine Fontaine, Celine Vazart, Virginie Decaulne, Francis Rousseau, Bernard Courtieu, Francois Liebaert, Andreas Jung, Daniel Neureiter, Raphaële Thiébaut, Sebastian Stintzing
Journal: Journal of Clinical Oncology (2016)

3516 Background: MiR 31 3p expression has been shown to be predictive of survival in RASwild-type (WT) mCRC patients treated with anti-EGFR therapies. We aimed to validate the predictive value of miR 31 3p in FIRE-3, a randomized clinical trial, based on a cut-off threshold of miR 31 3p expression identified in previous studies. Methods: MiR 31 3p expression was measured by qRTPCR after extraction from 370 RAS WT paraffin-embedded tumor samples. 191 patients were treated with FOLFIRI plus bevacizumab and 179 FOLFIRI plus cetuximab in first-line therapy. Patients were defined as low or high miR 31 3p expressors based on a pre-specified cut-off threshold. Primary objective was to assess cetuximab benefit on overall (OS) and progression free survival (PFS) in the low expressor group (a = 0.025). Interaction between miR 31 3p expression and treatment was tested (a = 0.10) and assessed using a propensity score. Secondary objectives were to evaluate treatment effect on survival in high expressors and objective response rate (ORR) in both high and low expressors. Cox and logistic multivariate regressions were used to estimate hazard ratios (HR) and odds ratios (OR) respectively. Results: In low expressors (67% of studied patients), the risk of death was significantly decreased in patients treated with cetuximab as compared to bevacizumab (HR = 0.60 [0.42–0.85], p = 0.005; median OS: 39 vs. 28 months respectively). No significant difference was seen in high expressors (HR = 1.10 [0.70–1.75] p = 0.67; median OS: 20 months for both treatment arms). MiR 31 3p was found to be predictive of cetuximab effect on OS and PFS (interaction test: p = 0.07 and p = 0.08 respectively). For patients whom ORR data were available, we showed a benefit for cetuximab in low expressors (OR = 3.37 [1.70–6.67] p = 0.0005). Furthermore, miR 31 3p was found to be predictive of cetuximab effect on ORR (significant interaction: p = 0.06). Conclusions: Low miR 31 3p expressors have a significantly better OS and ORR when treated with FOLFIRI plus cetuximab as compared to FOLFIRI plus bevacizumab. MiR 31 3p is predictive of cetuximab effect on OS, PFS and ORR and should be used to select patients who will have greater benefit from cetuximab therapy.
Diabetes and intermediate hyperglycaemia in Kisantu, DR Congo: a cross-sectional prevalence study
Authors: Muelo Telo Muyer, Erik Muls, Mali Ali Mapatano, R Makulo, M Mvitu, W Kimenyembo, M Mandja, P Kimbondo, E O Bieleli, K W Kaimbo, Frank Buntinx
Journal: BMJ (2012)
High Expression of IL-17 and Elevated High-Sensitivity C-Reactive Protein Predict Tumor Progression in Unresectable Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization
Authors: M.J. Song, S.H. Bae, H.J. Ahn, J.W. Jang, J.Y. Choi, S.K. Yoon
Journal: Journal of Hepatology (2016)
Dendritic cell based vaccine therapy of melanoma
Authors: N. N. Petenko, I. N. Mikhaylova, G. Z. Chkadua, E. V. Ogorodnokova, L. Y. Vishnyakova, S. A. Hatirev, E. A. Cheremushkin, Z. G. Kadagidze, L. V. Demidov, A. Y. Baryshnikov
Journal: Journal of Clinical Oncology (2007)

3077 Background: Vaccination with dendritic cells (DC) expressing tumor antigens is considered to be a possible strategy to induce anti-tumour immune responses in treatment of melanoma. Methods: 42 stage III and IV melanoma patients were enrolled into the study receiving autologous monocyte-derived DCs primed with autologous tumor lysate. DCs displayed mature phenotype. 75% of recruited pts had disease progression after conventional treatments modalities. Pts demographic characteristics wear: age 26–82 years (mean 54), male/female ratio = 24/18. Arm A included 17 pts treated with DC vaccine in therapeutic regimen (III stage - 2 pts, IV stage - 15 pts). Arm B consisted of 25 pts receiving DC vaccine after radical metastasectomy (III stage - 10 pts, IV stage - 15 pts). DC were administered s.c. q 2–4 weeks until disease progression in a dose of 1,0–5,0x10(6) cells. Pts who received = 4 vaccinations were evaluated, totally - 33 pts (79%) were considered evaluable. The vaccine therapy was evaluated for safety, tolerability and clinical effectiveness. Results. DCs vaccine was safe and well tolerated. Toxicity included flu-like syndrome (1 grade CTC), transitory hyperemia and itching in the sites of injections (1 grade CTC). 13 of 17 pts were evaluable in arm A, they received 210 vaccinations (from 4 to 21 per pts, mean 10,5). We observed 15,4% overall clinical response (1 complete and 1 partial response) and 38% stabilization of disease (lasting = 2 mos). 1- year survival, median survival were 42,5% and 9,5 mos, respectively. Follow-up 4–39+ mos. Among 20 evaluable pts in arm B who received 205 vaccinations (from 4 to 38 per pts, mean 15,8) median time to progression was 10 mos, 1-year survival - 84%, at a median follow- up of 12 mos (3–20+) disease free survival was 45%. Conclusion: DCs vaccine therapy is safe and lacks serious adverse effects. Melanoma pts with regional and distant metastasis demonstrated moderate clinical effectiveness in response to specific vaccine therapy. No significant financial relationships to disclose.
Quantification of Hepatitis B Core-Related Antigen is More Useful than Quantitative HBSAG for Identification of Inactive HBSAG Carriers
Authors: M.R. Barciela, M. Bes, M. Homs, D. Tabernero, R. Casillas, S. Sauleda, L. Nieto, F. Rodríguez-Frías, R. Esteban, M. Buti
Journal: Journal of Hepatology (2016)
Eggs or peanuts in early infant diet may cut allergy risk
Authors: Jacqui Wise
Journal: BMJ (2016)

Introducing eggs or peanuts early into infants’ diet is associated with a lower risk of developing egg or peanut allergy, says a systematic review of the evidence published in JAMA .1

The review found “moderate certainty” evidence that introducing eggs to the infant diet at 4 to 6 months was associated with reduced egg allergy and that introducing peanuts at 4 to 11 months was associated with reduced peanut allergy when compared with later introduction of these foods.

Infant feeding guidelines have moved away from advising parents to …
Is Protein Malnutrition a Negative Prognostic Factor in Compensated Cirrhotic Patients? A Retrospective Analysis Answering to the Proposal of the Italian Consensus on Portal Hypertension (Baveno VI)
Authors: B. Lattanzi, C. Lucidi, V. Di Gregorio, S. Nardelli, S. Gioia, O. Riggio, M. Merli
Journal: Journal of Hepatology (2016)
The Role of Serum Alphafetoprotein Determination in HCV-Cirrhosis after Antiviral Treatment
Authors: C. Della Corte, R. D’ambrosio, N. Piazza O Sed, A. Sangiovanni, A.M. Aghemo, M.A. Iavarone, S. De Nicola, M. Colombo
Journal: Journal of Hepatology (2016)
P0443 : Hyperammonemia activates human hepatic stellate cells and is a target for treatment of portal hypertension
Authors: F. De Chiara, R. Jalan, V. Balasubramaniyan, F. Andreola, M. Malago’, M. Pinzani, R.P. Mookerjee, K. Rombouts
Journal: Journal of Hepatology (2015)
Alox-5 As a Potent Therapeutic Target on Overcoming TKI-Resistance in Chronic Myeloid Leukemia with T315I Mutation in Bcr-Abl
Authors: Jishi Wang, Dan Ma, Ping Wang, Weibing Wu, Lu Cao, Tangsheng Lu, Jiangyuan Zhao, Qin Fang
Journal: Blood (2015)
Gemcitabine plus cisplatin (GP) versus 5-FU plus cisplatin (FP) as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC): A randomized, open-label, multicenter, phase III trial.
Authors: Li Zhang, Gengsheng Yu, Jun Jia, Peijian Peng, Qing Lin, Xuping Xi, Jiewen Peng, Mingjun Xu, Dongping Chen, Xiaojun Lu, Rensheng Wang, Xiaolong Cao, Xiaozhong Chen, Zhixiong Lin, Jian ping Xiong, Qin Lin, Conghua Xie, Zhihua Li, Chong Zhao, Shaodong Hong
Journal: Journal of Clinical Oncology (2016)

6007 Background: There are no well-established first-line chemotherapy regimens for recurrent or metastatic (R/M) NPC. Several small phase II trials suggest that GP has promising efficacy and acceptable toxicities. This phase III trial compared the efficacy and safety of GP versus FP as first-line therapy for patients with R/M NPC. This trial has been selected as “Trials in Progress” and presented in the poseter session in 2015 ASCO meeting (Abstract No. TPS6098). Methods: Eligible patients were randomized in 1:1 ratio to receive either GP (gemcitabine 1 g/m2 on days 1, 8, cisplatin 80 mg/m2 on day 1, q3w) or FP regimens (5-FU 4 g/m2 CIV over 96 hours, cisplatin 80 mg/m2 on day 1, q3w) for up to 6 cycles. The primary endpoint was progression-free survival (PFS). Secondary endpoints include overall survival (OS), objective response rate (ORR), safety and quality of life. Results: From February 2012 to October 2015, 362 patients from 22 institutions were randomly assigned to GP (n = 181) or FP (n = 181) group. Baseline characteristics were similar between both arms. The median PFS was 6.83 months in the GP group and 5.70 months in the FP group (HR = 0.57; 95% CI [0.46-0.71]; p < 0.0001). At 1 year, the PFS rate was 21% (95% CI, 18 to 24) with GP versus 6% (95% CI, 4 to 8) with FP. This effect was consistent for the best ORR (GP 68.3% versus FP 47.1%; p = 0.0001). The most common grade ≥ 3 related adverse events (AEs) were leukopenia (21.1%) and thrombocytopenia (11.1%) with GP and mucositis (12.9%) with FP. Treatment discontinuation due to related AEs was similar between both arms (GP 3.9% versus FP 5.5%; p = 0.458). Conclusions: First-line GP significantly improved PFS compared to FP in R/M NPC. Consistent benefit was seen with ORR. AEs were manageable with similar low discontinuation rates in both arms. Updated and OS data will be presented at ASCO meeting. Clinical trial information: NCT01528618.